EMCURE

Emcure’s stock price (NSE) is ₹ 1,361.90. 52-week range: low ₹ 889, high ₹ 1,520. P/E Ratio: 31.38 Price-to-Book (P/B): 5.42 Dividend yield: ~0.22% Valuation is rich: With P/E 31× and P/B 5.4×, the stock is not cheap — downside if growth disappoints. Pharma risk: Regulatory risk, R&D risk, pricing pressure, and competition are always big for drugmakers. Dependence on partnerships: The Novo Nordisk tie-up is promising but execution risk is non-trivial (commercialisation, regulatory, pricing). CapEx / cash risk: To maintain growth, they may need to invest heavily (R&D, manufacturing) — any misstep could hurt cash flows. Acquisition risk: The Zuventus acquisition is large; if integration fails or if minority purchase is expensive, value could be destroyed.